[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"G. d'Annunzio University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":402},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,76,108,130,153,185,209,238,266,292,314,330,351,375],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100643027","interactive-educational-video-for-paediatric-type-1-diabetes-100643027",false,"NCT07639307","Interactive Educational Video for Paediatric Type 1 Diabetes","The Efficacy of Interactive Videos in the Education of Paediatric Patients With Type 1 Diabetes: A Randomised Controlled Trial.","Intedu","Inclusion Criteria:\n\n* Male and female children aged between 8 and 14 years\n* Diagnosis of type 1 diabetes mellitus for at least 6 months\n* Ability to understand and communicate in Italian\n* Absence of psychiatric disorders\n* Absence of cognitive impairment\n* Ability to use digital devices (e.g., computer)\n* Written informed consent for study participation and personal data-processing provided by both parents or the legal guardian\n\nExclusion Criteria:\n\n* Age younger than 8 years or older than 14 years\n* Diagnosis of type 1 diabetes mellitus for less than 6 months\n* Inability to understand or communicate in Italian\n* Presence of psychiatric disorders\n* Presence of cognitive impairment\n* Inability to use digital devices (e.g., computer)\n* Refusal of assent by the child\n* Failure to provide written informed consent for study participation and personal data processing by both parents or the legal guardian","ALL","8 Years","14 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary aim of this study is to evaluate the effectiveness of an interactive educational video (Luca's Journey: Managing Type 1 Diabetes) delivered in addition to the standard educational programme, in improving metabolic control in children with type 1 diabetes mellitus, specifically focusing on the change in glycated haemoglobin (HbA1c) levels between baseline (T0) and six-month follow-up (T3).\n\nThe study will also assess the effectiveness of the intervention in improving fasting blood glucose levels, frequency of hypoglycaemic and hyperglycaemic episodes, clinical and anthropometric variables (blood pressure, body weight, BMI, and waist circumference), acquisition of nutritional knowledge based on recommendations for the management of type 1 diabetes, and adherence to the main type 1 diabetes management activities.\n\nThe secondary objectives were to compare the two educational modalities (intervention vs. standard educational programme) in terms of: (i) mean between-group difference in the change in fasting blood glucose levels and frequency of hypoglycaemic and hyperglycaemic episodes; (ii) mean between-group difference in the change in clinical and anthropometric variables; (iii) acquisition of nutritional knowledge based on recommendations for the management of type 1 diabetes; and (iv) adherence to the main type 1 diabetes management activities.\n\nThe main research questions addressed in this study are:\n\nDoes the interactive educational video improve metabolic control, as measured by HbA1c levels, in children with type 1 diabetes compared to standard education alone? Does the intervention lead to a greater reduction in fasting blood glucose levels and a lower frequency of hypoglycaemic and hyperglycaemic episodes? Does the intervention improve clinical and anthropometric variables compared to standard education alone? Does the intervention lead to a greater acquisition of nutritional knowledge in children with type 1 diabetes? Does the intervention improve adherence to the main type 1 diabetes management activities, including insulin administration, blood glucose monitoring, dietary behaviours, and physical activity? Both study groups will receive the standard in-person educational programme, as routinely delivered at the outpatient clinic of the Regional Centre for Paediatric Diabetology of the \"SS. Annunziata\" University Hospital in Chieti. Participants assigned to the intervention group will additionally receive a 25-minute interactive educational video immediately following the standard educational session. The interactive video follows a child with type 1 diabetes through everyday situations, inviting participants to make decisions at key moments and explore the consequences of different behavioural choices related to diabetes management.",[28,29],"Diabete Type 1","Educational Videos",[28,29,31,32,33],"metabolic control","Glycemic Control","children","NOT_YET_RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":22},"2027-01",{"date":42,"type":22},"2028-01",{"name":44,"class":45},"G. d'Annunzio University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100642993","telesm-edunursing-a-personalised-nursing-intervention-for-people-with-multiple-sclerosis-100642993","NCT07640698","TELESM-edu.Nursing: a Personalised Nursing Intervention for People With Multiple Sclerosis","TELESM-edu.Nursing: Efficacy of a Personalised Nursing Intervention for the Management of People With Multiple Sclerosis","TELESM-edu","Inclusion Criteria:\n\n* Patients of both sexes (male and female)\n* Age 18 years or older\n* Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), or secondary progressive multiple sclerosis (SPMS)\n* Currently receiving pharmacological treatment for multiple sclerosis\n* Expanded Disability Status Scale (EDSS) score of 7.5 or lower\n* Ability to read and understand Italian\n* Ability to provide written informed consent\n* Access to a suitable device (smartphone, tablet, or computer with a webcam)\n* Access to a home internet connection\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Expanded Disability Status Scale (EDSS) score higher than 7.5\n* Presence of psychiatric disorders that may interfere with participation in the study\n* Presence of cognitive impairment that may interfere with participation in the study","18 Years",{"count":21,"type":22},[25],"The primary aim of this study is to evaluate the impact of the telenursing intervention \"TELESM-edu.nursing\" on people with Multiple Sclerosis (pwMS), specifically focusing on their navigational capacity within the healthcare system (Navigation Health Literacy) and their perceived level of Health Literacy.\n\nThe study will also assess the effectiveness of the intervention in improving patient satisfaction with current therapy, patients' beliefs and attitudes towards the prescribed therapeutic regimen, satisfaction of informational needs, trust in nurses, and degree of disability.\n\nThe secondary objective is to evaluate the feasibility and sustainability of a personalised telenursing programme for pwMS. Feasibility will be assessed based on: (I) the ability to recruit and retain participants, measured through adherence rates and dropout rates in the intervention group; (II) participants' acceptability, usability, and satisfaction with the intervention; and (III) healthcare staff satisfaction and perceived usability of the intervention.\n\nThe main research questions addressed in this study are:\n\nDoes the \"TELESM-edu.nursing\" intervention improve patients' Navigation Health Literacy and overall Health Literacy levels? Does the intervention improve patient satisfaction with therapy and fulfilment of informational needs? Does the intervention positively influence patients' beliefs and attitudes towards their treatment? Does the intervention increase trust in nurses? What is the impact of the intervention on patients' level of disability? Is the telenursing programme feasible, acceptable, and sustainable for both patients and healthcare professionals?\n\nBoth study groups will receive the standard in-person informational and educational programme, as well as routine follow-up visits according to the established care pathway. Participants assigned to the intervention group will additionally receive a personalised educational programme lasting six months. This programme will be delivered monthly by a nurse through educational video pills and nurse-led teleconsultations.\n\nParticipants will be required to watch the video pills and take part in teleconsultations.",[59,60],"Multiple Sclerosis (MS)","Telenursing",[60,62,63,64,65,66,67,68],"Navigation Health Literacy","Health Literacy","Needs Assessment","Nurses","Therapeutics","Multiple sclerosis","Disability Evaluation",{"date":70,"type":38},"2026-06-11",{"date":72,"type":22},"2026-07",{"date":74,"type":22},"2027-06",{"name":44,"class":45},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100505212","clinical-effectiveness-of-biologic-agents-as-an-adjunct-to-non-surgical-periodontal-therapy-of-intrabony-defects-100505212","NCT05858411","Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects","Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III or IV (grades A to C),\n* non-smokers or former smokers who quit at least 1 year ago, and\n* had not received any periodontal treatment in the 3 months prior to recruitment;\n* Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);\n* One and two wall infrabony defects at screening radiograph and periodontal charting.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression;\n* Subjects requiring antibiotic prophylaxis;\n* 3-wall infrabony defects;\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;\n* Presence of furcation defect;\n* Chronic intake of NSAIDs or steroids, currently;\n* Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.",{"count":84,"type":22},88,[25],"The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST).\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.\n\nStandardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.",[88,89,90,91],"Periodontal Diseases","Periodontal Attachment Loss","Pocket, Periodontal","Intrabony Periodontal Defect",[93,94,95,96,97],"rhPDGF","Growth factors","Periodontal regeneration","L-PRF","Enamel Matrix Derivatives","RECRUITING","2026-05-25",{"date":101,"type":38},"2026-05-28",{"date":103,"type":38},"2023-01-08",{"date":105,"type":22},"2027-09-01",{"name":44,"class":45},1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":107},"100623020","crown-removal-in-non-surgical-peri-implantitis-therapy-a-randomized-trial-100623020","NCT07391202","Crown Removal in Non-Surgical Peri-Implantitis Therapy: A Randomized Trial","Effectiveness of Non-Surgical Mechanical Therapy of Peri-Implantitis With or Without Prosthetic Crown Removal: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with at least one implant diagnosed with peri-implantitis (Berglundh et al., 2018);\n* Patients with a crown on the implant affected by peri-implantitis that is removable;\n* Patients who have not received non-surgical peri-implant therapy in the previous 6 months;\n* Patients who have not taken systemic antibiotic therapy in the previous 3 months.\n\nExclusion Criteria:\n\n* Full-Mouth Plaque Score (FMPS) \\> 30% at the time of non-surgical therapy;\n* Pregnant or breastfeeding women;\n* Relevant medical history, in the opinion of the examining clinician, that could affect the outcome of non-surgical peri-implant therapy;\n* Smoking patients consuming \\> 10 cigarettes\u002Fday.",true,{"count":117,"type":22},36,[25],"The aim of this single-blind, randomized controlled clinical trial is to evaluate whether removal of the prosthetic crown influences the clinical effectiveness of non-surgical mechanical therapy in implants affected by peri-implantitis.\n\nThe study is designed to compare changes in several clinical and radiographic parameters between baseline and follow-up examinations at 3, 6, and 12 months. The primary outcome measure will be the mean peri-implant probing depth (PIPD). Secondary outcomes will include changes in gingival recession (REC), radiographic marginal bone level (MBL), modified bleeding index (mBI), and additional patient-related variables.",[121],"Peri-implantitis","2026-05-02",{"date":124,"type":38},"2026-05-07",{"date":126,"type":38},"2026-04-20",{"date":128,"type":22},"2027-07-31",{"name":44,"class":45},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":107},"100636643","brain-connectivity-and-perceptive-surfaces-in-chronic-low-back-pain-super-rmnf-100636643","NCT07568353","Brain Connectivity and Perceptive Surfaces in Chronic Low Back Pain (SUPER-RMNf)","Lombalgia Cronica Aspecifica e Superfici Percettive: Rappresentazione Corticale Del Tronco Nella Risposta al Trattamento Riabilitativo - Studio Quasi-sperimentale Non Randomizzato","Inclusion Criteria:\n\n* Aged between 18 and 45 years\n* Right-handed dominance\n* Good general health condition\n* Ability to provide written informed consent.\n\nFor the patient group:\n\n\\- Clinical diagnosis of non-specific chronic low back pain with a duration of more than 3 months\n\nFor the control group:\n\n\\- Healthy volunteers without a history of chronic pain\n\nExclusion Criteria:\n\n* Contraindications to 3T Magnetic Resonance Imaging, such as pacemakers or non-compatible metallic implants\n* Pregnancy or breastfeeding\n* Presence of significant neurological or psychiatric pathologies\n* Current use of psychoactive medications.\n* Sensory or motor disorders of the lower limbs that prevent interaction with the perceptive surface.\n* Unstable or acute clinical conditions.\n* Inability to remain still during the MRI scanning procedure","45 Years",{"count":139,"type":22},40,[25],"Rationale:\n\nChronic Low Back Pain (CLBP) is often associated with \"cortical reorganization,\" where the brain's map of the back becomes less precise. This phenomenon contributes to the persistence of pain and reduced body awareness. While traditional rehabilitation focuses on the physical structure of the spine, neurocognitive approaches use \"perceptive surfaces\" to provide specific tactile and proprioceptive feedback, aiming to \"retrain\" the brain's representation of the trunk.\n\nObjective and Hypothesis:\n\nThe primary goal of this study is to investigate how the brain responds to stimulation from these perceptive surfaces in patients with CLBP compared to healthy individuals. The investigators hypothesize that using these surfaces will lead to immediate changes in functional brain connectivity, particularly in areas responsible for body awareness and pain processing (somatosensory and salience networks).\n\nStudy Procedures:\n\nThe study will involve 20 patients with chronic non-specific low back pain and 20 healthy volunteers. All participants will undergo a Functional Magnetic Resonance Imaging (fMRI) session. During the scan, participants will be placed on a specialized perceptive surface. Brain activity and connectivity will be measured at rest and during specific tactile stimulation. Additionally, advanced imaging techniques (SANDI model) will be used to look at the microscopic structure of brain cells (neurons).\n\nClinical Impact:\n\nBy comparing the two groups, the study aims to identify specific \"brain signatures\" of recovery. This could help clinical professionals understand if perceptive surfaces can effectively restore cortical maps, leading to better personalized rehabilitation strategies for chronic pain.",[143,144],"Low Back Pain","Healthy","2026-04-30",{"date":147,"type":38},"2026-05-05",{"date":149,"type":22},"2026-05-01",{"date":151,"type":22},"2026-07-01",{"name":44,"class":45},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":161,"minAge":54,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100596661","mindfulness-based-rehabilitation-in-a-university-museum-setting-to-reduce-pain-and-improve-quality-of-life-in-women-with-fibromyalgia-a-randomized-controlled-trial-100596661","NCT07048366","Mindfulness-based Rehabilitation in a University Museum Setting to Reduce Pain and Improve Quality of Life in Women With Fibromyalgia: a Randomized Controlled Trial","Art as a Therapeutic Tool in the Rehabilitation of Patients With Fibromyalgia: the University Museum as a Setting for an Integrative Medicine Program - a Randomized Controlled Trial","FMmuseo","Inclusion Criteria:\n\n* Female patients\n* Diagnosis of Fibromyalgia Syndrome according to 2016 criteria\n* Muscle pain Visual Analogue Scale (VAS) score greater than 5 in the last month\n* Age between 18 and 60 years\n* Absence of other chronic, widespread, or localized painful conditions\n* Absence of any other condition that might affect pain perception (e.g., diabetes)\n* Absence of neurological or psychiatric conditions that might affect study participation\n* Absence of current or past oncological diseases in the last 5 years\n* Absence of corticosteroid therapy in the last 30 days\n* Absence of NSAID (Non-Steroidal Anti-Inflammatory Drugs) and analgesic therapy in the last 4 days\n* Absence of pregnancy and breastfeeding for the entire duration of observation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of severe scoliosis or kyphoscoliosis\n* Previous spinal surgeries or sequelae of vertebral fractures\n* Presence of lumbosciatalgia (sciatica-like pain in the lower back) at the time of the visit\n* Presence of osteoporosis\n* Presence of neurological or psychiatric conditions\n* Current therapy with corticosteroids and\u002For NSAIDs and\u002For analgesics\n* Pregnancy or breastfeeding","FEMALE","60 Years",{"count":164,"type":22},44,[25],"This research study aims to investigate whether art and integrative medicine, within a unique setting like a university museum, can offer a new approach to help women suffering from fibromyalgia. Fibromyalgia is a chronic condition causing widespread pain and other symptoms such as fatigue and sleep disturbances. The question this study seeks to answer is: Is an 8-week rehabilitation program, based on mindfulness and body awareness techniques, conducted at the University Museum of the G. d'Annunzio University, effective in reducing pain and improving the quality of life (physical and mental well-being) and coping abilities in female fibromyalgia patients? Participants will be randomly assigned to either receive this program in the museum or to a control group.",[168,169,170],"Fibromyalgia","Chronic Pain","Musculoskeletal Pain",[168,172,173,174,175],"Rehabilitation","Integrative Medicine","Art Therapy","Museums","2026-04-25",{"date":178,"type":38},"2026-04-28",{"date":180,"type":38},"2025-11-27",{"date":182,"type":22},"2026-07-31",{"name":44,"class":45},2,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":208,"locationsCount":107},"100633270","predictive-role-of-the-full-mouth-plaque-score-on-the-outcomes-of-non-surgical-periodontal-therapy-100633270","NCT07524504","Predictive Role of the Full-mouth Plaque Score on the Outcomes of Non-surgical Periodontal Therapy.","Predictive Role of Full-Mouth Plaque Score on the Outcomes of Non-Surgical Periodontal Therapy: A Prospective Cohort Study","Inclusion Criteria:\n\n* Diagnosis of periodontitis according to current guidelines.\n* Age between 18 and 80 years.\n\nExclusion Criteria:\n\n* Patients who have previously received periodontal treatment.\n* Patients currently on antibiotic therapy or who have taken antibiotics in the past 3 months.\n* Pregnant or breastfeeding women.\n* Presence of systemic diseases or use of medications in which periodontal treatment is contraindicated or could affect study outcomes (e.g., antihypertensives, antiepileptics, immunosuppressants).","80 Years",{"count":194,"type":22},100,"OBSERVATIONAL","Oral hygiene quality is a key determinant of outcomes in both non-surgical and surgical periodontal therapy. Previous studies have demonstrated the negative impact of site-specific plaque accumulation on periodontal parameters. However, to the best of our knowledge, no studies have specifically investigated the correlation between plaque index and the percentage reduction in periodontal pocket depth, nor its association with other periodontal clinical parameters.\n\nThe aim of this study is to evaluate the relationship between plaque index and the percentage reduction in periodontal pockets, as well as its association with key periodontal parameters.\n\nFollowing baseline data collection, patients will undergo non-surgical periodontal therapy in accordance with current guidelines. Clinical outcomes will be reassessed at 3, 6, 9, and 12 months post-treatment.",[198],"Periodontitis",[198,200,201],"Non-surgical periodontal therapy","Re-evaluation","2026-04-08",{"date":204,"type":38},"2026-04-13",{"date":149,"type":22},{"date":207,"type":22},"2027-12-15",{"name":44,"class":45},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":161,"minAge":54,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":184},"100612813","two-previous-cesarean-and-vaginal-birth-before-and-after-starting-training-and-protocols-100612813","NCT07258459","Two Previous Cesarean and Vaginal Birth Before and After Starting Training and Protocols","Trial of Labor After Two CS Before and After Training a Protocol Introduction","TOLA2C Train","Inclusion Criteria:\n\n* pregnant women\n* pregnancy above 34 weeks' gestation\n* cephalic presentation of the fetus\n* singleton and twins\n* diamniotic twins\n* 2 previous CS\n* more than 18 months from last CS\n* no other indication to CS\n\nExclusion Criteria:\n\n* pregnancy below 34 weeks' gestation\n* breech baby\n* triplets or high order multiple pregnancies\n* more than 2 previous CS\n* less than 18 months from last CS\n* precence of other indications to CS (i.e. maternal diseases, placenta previa, etc.)",{"count":218,"type":22},2016,"In 2015 ObGyn Dept of Santo Spirito Hospital in Pescara (Italy) started protocol for previous CS vaginal birth. In 2021 was started a protocol for training on obstetric emergencies and protocol on two previous cesarean was endorsed. Patients attending birth in Pescara with two previous from january 2016 to December 2020, and from january 2021 to december 2025 were collected. A different counseling approach was adopted from 2021. Women's acceptance of trial of labor and maternal and fetal outcomes were collected.",[221,222,223],"Cesarean Delivery Affecting Fetus or Newborn","Labor (Obstetrics)--Complications","Hemorrhagic Complications",[225,226,227,228,229],"previous CS","trial of labor","maternal outcomes","fetal outcomes","neonatal outcomes","2025-11-20",{"date":232,"type":38},"2025-12-02",{"date":234,"type":38},"2016-01-01",{"date":236,"type":22},"2026-01-01",{"name":44,"class":45},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":246,"maxAge":54,"enrollmentInfo":247,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":107},"100588936","biofeedback-based-system-to-enhance-robotic-assisted-gait-training-in-children-with-cerebral-palsy-100588936","NCT06947889","Biofeedback Based System to Enhance Robotic Assisted Gait Training in Children With Cerebral Palsy","AID2GAIT: Biofeedback Based System to Enhance Robotic Assisted Gait Training in Children With Cerebral Palsy","AID2GAIT","Inclusion Criteria:\n\nChildren with cerebral palsy aged 3 to 18 years who have a GMFCS level from I to V, with the ability to express discomfort or pain and understanding simple instructions\n\nExclusion Criteria:\n\n* Medical problems that could interfere with training and restrictions on the use of the robotic device;\n* severe lower limb conditions: muscle contractures, instability or subluxation of the hip;\n* recent botulinum toxin A injections to the lower limbs;\n* uncontrolled seizures;\n* open skin disorders and vascular disorders of the lower limbs.\n* Contraindications to gait rehabilitation treatment with Lokomat (e.g. weight \\\u003C10 kg, non-consolidated fractures, cognitive deficits limiting communication).\n* Contractures of fixed joints that limit the range of motion of the orthoses\n* Inability to properly adjust the harness and\u002For orthoses","3 Years",{"count":248,"type":22},11,"The AID2GAIT project aims to develop a biofeedback system with the aim of improving the outcomes of robot-assisted gait training (RAGT) in pediatric patients with cerebral palsy. The physiological signals of children during RAGT therapy sessions, acquired through non-invasive technologies, will be analyzed. These technologies specifically are:\n\n* wearable technology (smartwatch), from which the HRV (Heart Rate Variability) signal will be measured;\n* infrared thermography, from which the temperature in salient facial regions will be obtained;\n* fNIRS (functional near-infrared spectroscopy), from which information on brain activity and its changes over time will be obtained.\n\nInformation on the kinematics of the exoskeleton used during RAGT will be extracted.\n\nThe RAGT will be performed using the Lokomat orthosis (Hocoma), the most widely used exoskeleton in rehabilitation that facilitates a bilaterally symmetrical gait, as the individual actively tries to advance each limb during walking, combined with a patented dynamic body weight support system.",[251,252],"Cerebral Palsy Infantile","Robotic Assisted Gait Training",[252,254,255,256,257],"Biofeedback","Infant Cerebral Palsy","Human-Robot Interaction","Exoskeleton","2025-04-24",{"date":260,"type":38},"2025-04-27",{"date":262,"type":38},"2024-07-01",{"date":264,"type":22},"2026-02-28",{"name":44,"class":45},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":192,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":107},"100570018","optimizing-clinical-outcomes-in-caf--sctg-the-impact-of-compressive-sutures-100570018","NCT06701786","Optimizing Clinical Outcomes in CAF + SCTG: the Impact of Compressive Sutures","Compressive Sutures Improve Clinical Outcomes in CAF + SCTG for Treatment of RT1 Recessions\"","Inclusion Criteria:\n\n* systemic factors (no systemic diseases; no coagulation disorders; no medications affecting periodontal status in the previous 6 months; no pregnancy or lactation\n* never smokers\u002Fformer smokers \\>=10years\n* a full-mouth plaque score (FMPS)and a full-mouth bleeding score (FMBS) lower than 15%\n* no periodontal surgery on the experimental sites\n* \\>= 20 teeth without mobility\n* no presence of cervical carious lesions or periapical lesions at experimental sites\n* at least one RT1 buccal gingival recession\n\nExclusion Criteria:\n\n* systemic diseases\n* coagulation disorders\n* medications affecting periodontal status in the previous 6 months\n* pregnancy or lactation\n* Smokers",{"count":139,"type":22},[25],"This randomized controlled clinical trial aims to evaluate the additional effect on clinical outcomes of compressive sutures associated with coronally advanced flap (CAF) and subepithelial connective tissue graft (SCTG) for the treatment of RT1 gingival recessions (as classified by Cairo et al.).\n\nForty patients presenting with at least one RT1 recession will be enrolled in the study. Twenty participants will undergo CAF + SCTG with compressive sutures while the other 20 participants will receive the same procedure without compressive sutures. The primary outcome, complete root coverage (CRC), will be assessed six months after treatment.\n\nAdditional clinical parameters, including gingival recession (GR), clinical attachment level (CAL), pocket depth (PD), keratinized tissue width (KT), keratinized tissue thickness (GT), and Root Coverage Esthetic Score (RES), will be evaluated at baseline and at the six-month follow-up.\n\nPatient-reported outcomes (PROs) will also be measured, including the degree of general discomfort (D) experienced, assessed on a Visual Analog Scale (VAS) from 0 to 10, as well as patient-reported aesthetic satisfaction (PRES) and overall treatment satisfaction (OTS), both quantified on a VAS scale from 0 to 10.",[277,278,279],"Gingival Recessions","Gingival Recession, Mucogingival Surgery","Suture",[281,282,283,279],"Periodontal Plastic Surgery","Gingival recession","Coronally Advanced Flap","2024-11-19",{"date":286,"type":38},"2024-11-22",{"date":288,"type":22},"2024-12-01",{"date":290,"type":22},"2025-11-30",{"name":44,"class":45},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":192,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":107},"100570019","clinical-evaluation-of-gingival-biotype-changes-using-a-coronally-advanced-flap-caf-in-combination-with-leucocyte-and-platelet--rich-fibrin-l-prf-membranes-of-different-thickness-for-the-treatment-of-rt1-gingival-recession-a-randomized-controlled-clinical-trial-100570019","NCT06701799","Clinical Evaluation of Gingival Biotype Changes Using a Coronally Advanced Flap (CAF) in Combination with Leucocyte and Platelet- Rich Fibrin (L-PRF) Membranes of Different Thickness for the Treatment of RT1 Gingival Recession: a Randomized Controlled Clinical Trial.","CAF in Association with Different Thickness of L-PRF Membranes of for the Treatment of RT1 Gingival Recession: a Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Systemic factors (no systemic diseases; no coagulation disorders; no medications affecting periodontal status in the previous 6 months; no pregnancy or lactation)\n* Never smokers\u002Fformer smokers \\>=10years\n* Full-mouth plaque score (FMPS)and a full-mouth bleeding score (FMBS) lower than 15%\n* No periodontal surgery on the experimental sites\n* \\>= 20 teeth without mobility\n* No presence of cervical carious lesions or periapical lesions at experimental sites\n* At least one RT1 buccal gingival recession\n\nExclusion Criteria:\n\n* Systemic diseases\n* Coagulation disorders\n* Medications affecting periodontal status in the previous 6 months\n* Pregnancy or lactation\n* Smokers",{"count":139,"type":22},[25],"Gingival thickness plays a key role not only in the etiology but also in the treatment of gingival recessions. More recently, authors reported that as the gingival thickness decreases, the gingival recession severity increases . When gingival inflammation occurs, if the tissue is thin the consequent destruction can quickly produce a gingival recession (GR) .\n\nWhen treating a gingival recession, the clinician should aim not only to completely cover the exposed root surface but also to prevent a future recession recurrence. The treatment gold standard is the CAF associated with connective tissue graft. This technique has demonstrated high rates in gingival recession reduction and positive predictability in obtaining complete root coverage. However, some disadvantages about this surgical approach can be easily highlighted: patients experience more discomfort, longer chair-time it's necessary and a second wound area is created. In this scenario, The Platelet rich in fibrin and leucocyte (L-PRF) could be a valuable alternative treatment of gingival defects. It's a platelet concentrate, obtained by a fast and simple procedure that does not require anticoagulant and bovine thrombin. It can also be categorized as a live tissue thanks to platelets, leukocytes, growth factors and stem cells trapped in a polymerized fibrin mesh. L- PRF is used in various fields of regenerative medicine; It promotes stabilization and revascularization of the flaps, contributes to soft tissue wound healing and reduces post-operative discomfort. The purpose of this study will be to evaluate if the different thickness of platelet- rich fibrin (L-PRF) membranes in association with a Coronally Advanced Flap (CAF), for the treatment of RT1 gingival recessions, may influence the Complete Root Coverage (CRC).",[303,304,278,96],"Mucogingival Defects","Recession, Gingival",[283,96,306,307,308],"Platelet concentrate","Gingival Recession","Gingival Biotype",{"date":286,"type":38},{"date":311,"type":22},"2024-11-30",{"date":290,"type":22},{"name":44,"class":45},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":192,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":329,"locationsCount":107},"100569757","different-suture-diameters-in-periodontal-plastic-surgery-100569757","NCT06698393","Different Suture Diameters in Periodontal Plastic Surgery","Impact of Different Polyamide Suture Diameter on Clinical Outcomes in Periodontal Plastic Surgery: a Randomized Controlled Trial",{"count":139,"type":22},[25],"This randomized controlled clinical trial aims to compare the clinical outcomes of using non-resorbable polyamide sutures of different diameters (3.0 vs. 6.0) for securing an advanced coronary flap (CAF) and subepithelial connective tissue graft (SCTG) in the treatment of RT1 gingival recessions (as classified by Cairo et al.).\n\nForty patients presenting with at least one RT1 recession will be enrolled in the study. Twenty participants will undergo CAF + SCTG sutured with non-resorbable polyamide thread of 3.0 diameter, while the other 20 participants (control group) will receive the same procedure sutured with a 6.0 diameter thread. The primary outcome, complete root coverage (CRC), will be assessed six months after treatment.\n\nAdditional clinical parameters, including gingival recession (GR), clinical attachment level (CAL), pocket depth (PD), keratinized tissue width (KT), keratinized tissue thickness (GT), and Root Coverage Esthetic Score (RES), will be evaluated at baseline and at the six-month follow-up.\n\nPatient-reported outcomes (PROs) will also be measured, including the degree of general discomfort (D) experienced, assessed on a Visual Analog Scale (VAS) from 0 to 10, as well as patient-reported aesthetic satisfaction (PRES) and overall treatment satisfaction (OTS), both quantified on a VAS scale from 0 to 10.",[307],"2024-11-18",{"date":326,"type":38},"2024-11-21",{"date":288,"type":22},{"date":290,"type":22},{"name":44,"class":45},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":4},"100567115","connective-tissue-graft-and-leucocyte---platelet-rich-fibrin-in-alveolar-ridge-preservation-100567115","NCT06663982","Connective Tissue Graft and Leucocyte - Platelet Rich Fibrin in Alveolar Ridge Preservation","Periosteal Inhibition Technique With Connective Tissue Graft and Leucocyte- Platelet Rich Fibrin in Alveolar Ridge Preservation: a Randomized Controlled Clinical Trial","* Age \\> 18 years old;\n* General good health (ASA I-II);\n* Adequate oral hygiene (Full Mouth Plaque Score ≤ 20%, Full Mouth Bleeding Score ≤ 20%);\n* Presence of one or more hopeless teeth requiring extraction.",{"count":338,"type":22},34,[25],"The purpose of our randomized controlled clinical trial is to evaluate radiographic bone dimensional changes and soft tissue healing and thickness after teeth extraction and the implementation of alveolar ridge preservation (RAP) procedures that will involve the application of L-PRF inside the socket in association with a connective tissue graft (CTG) used as a barrier with the periosteal inhibition technique (PI). The present experimental treatment (test group) will be compared with an active comparator (control group) which will involve the insertion of L-PRF alone inside the socket.",[342],"Alveolar Socket Preservation","2024-10-28",{"date":345,"type":38},"2024-10-29",{"date":347,"type":22},"2024-12-09",{"date":349,"type":22},"2025-07-31",{"name":44,"class":45},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":115,"sex":17,"minAge":54,"maxAge":192,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":107},"100564059","effectiveness-of-srp-lipo-curcumin-gel-for-the-treatment-of-stage-iii-periodontitis-100564059","NCT06624241","Effectiveness of SRP+ Lipo-curcumin Gel for the Treatment of Stage III Periodontitis.","Clinical Evaluation of Lipo-Curcumin Gel in Association with SRP for the Treatment of Stage III Periodontitis: a Randomized and Controlled Clinical Trial.","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III (grades A to C)\n* on-smokers or former smokers who quit at least 1 year ago, and had not received any periodontal treatment in the 3 months prior to recruitment\n* FMPS \\\u003C 20% at baseline\n* Furcation not involved\n* Not Pregnant or Lactating\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment\n* Chronic intake of NSAIDs or steroids, currently",{"count":139,"type":22},[25],"The aim of the present study is to clinically and radiographically compare the effectivness of Scaling and Root Plannig (SRP) in association with lipo-curcumin gel (LC) respect SRP+ lipo-gel (L), SRP+ discharged (D) gel and SRP alone.\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 40 patients will be recruited and randomly equally distributed into 4 groups: an experimental group treated with SRP + LC, a first control group treated with SRP + L, a second control group treated with SRP+D and a third control group SRP alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following SRP, experimental and control sites will be randomly chosen. The test sites will be t filled with a Lipo-Curcumin gel and sealed with cyanoacrylate. In the first control group the defects will be be filled with a Lipo gel and sealed with cyanoacrylate. In the second control sites he pocket defect will be filled with a discharged gel and sealed with cyanoacrylate, in the third control group SRP alone will be performed.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.",[88,362,89],"Periodontal Pocket",[364,365,366,198],"Curcumin","SRP","Liposome","2024-09-30",{"date":369,"type":38},"2024-10-02",{"date":371,"type":38},"2024-06-12",{"date":373,"type":22},"2025-09",{"name":44,"class":45},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":390,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":4},"100554171","integrative-intervention-strategies-for-binge-eating-in-patients-with-overweight-or-obesity-100554171","NCT06495619","Integrative Intervention Strategies for Binge Eating in Patients With Overweight or Obesity","Effectiveness of Integrative Intervention Strategies for Binge Eating in Patients With Overweight or Obesity: A Multidisciplinary Approach","BE-side","Inclusion Criteria:(1) age 18-65 years; (2) BMI≥25 kg\u002Fm2; (3) ability to read and write in Italian; (4) Binge Eating Disorder (BED) or subthreshold BED status.\n\n\\-\n\nExclusion Criteria: (1) current treatment for BE with a registered psychologist; (2) severe psychiatric disorders; (4) cognitive impairment; (5) pregnancy; (6) severe medical comorbidity.\n\n\\-","65 Years",{"count":194,"type":22},[25],"The main goal of the clinical trial is to compare the short- and long-term outcomes of three 12-week interventions among outpatients with overweight\u002Fobesity and binge eating (BE):\n\n1. treatment-as-usual for weight loss (TAU);\n2. combined TAU and guided self-help for improving eating behaviors (TAU+GSH);\n3. combined TAU, GSH, and biofeedback (TAU+GSH+BF). The primary outcomes will be self-reported reduction of days with objective BE episodes (OBEs).\n\nThe secondary outcomes will be impulsivity, emotion dysregulation, interoceptive awareness, distress, physiological correlates of arousal (skin conductance and heart rate variability), and inflammatory biomarkers.\n\nThe TAU+GSH arm is expected to be comparable to the TAU+GSH+BF arm in reducing the number of days with OBEs but is expected to be significantly less effective in improving secondary outcomes (impulsivity, emotional dysregulation, interoceptive awareness, distress, physiological inflammatory markers). The TAU arm is expected to show significant inferiority regarding the primary and secondary outcomes and cost-effectiveness compared to the TAU+GSH and TAU+GSH+BF conditions.",[388,389],"Binge Eating","Overweight and Obesity",[388,391,392,393,254],"Overweight","Obesity","Guided Self-Help","2024-07-03",{"date":396,"type":38},"2024-07-11",{"date":398,"type":22},"2024-08-01",{"date":400,"type":22},"2025-06-30",{"name":44,"class":45},""]